| Similar Articles |
|---|
 |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.   |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
The Motley Fool
June 4, 2007
Brian Orelli |
OXiGENE's Moving Ahead The drug maker reaches a deal with FDA on its lead compound. Investors, take note. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
February 26, 2008
Brian Orelli |
The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
The Motley Fool
March 31, 2009
Brian Orelli |
A Good Start for a Potential Blockbuster Novartis' FDA approval for Afinitor is nice, but it needs another indication to be a blockbuster. |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
April 9, 2008
Brian Orelli |
Russia Approves an Unproven Treatment Antigenics gains approval of Oncophage in Russia, making it the first pharmaceutical to gain approval of any cancer vaccine. |
BusinessWeek
January 30, 2006
Catherine Arnst |
Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk. |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
February 16, 2004
Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key. |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
March 22, 2005
Charly Travers |
Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
The Motley Fool
May 2, 2011
Tim Beyers |
Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment. |
The Motley Fool
April 27, 2004
Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
December 14, 2010
Brian Orelli |
An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
